Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas

BACKGROUND: Effective medical therapies are lacking for the treatment of neurofibromatosis type 1– related plexiform neurofibromas, which are characterized by elevated RAS–mitogen-activated protein kinase (MAPK) signaling. METHODS: We conducted a phase 1 trial of selumetinib (AZD6244 or ARRY-142886)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Main Authors: Dombi, Eva, Baldwin, Andrea, Marcus, Leigh J., Fisher, Michael J., Weiss, Brian, Kim, AeRang, Whitcomb, Patricia, Martin, Staci, Aschbacher-Smith, Lindsey E., Rizvi, Tilat A., Wu, Jianqiang, Ershler, Rachel, Wolters, Pamela, Therrien, Janet, Glod, John, Belasco, Jean B., Schorry, Elizabeth, Brofferio, Alessandra, Starosta, Amy J., Gillespie, Andrea, Doyle, Austin L., Ratner, Nancy, Widemann, Brigitte C.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5508592/
https://ncbi.nlm.nih.gov/pubmed/28029918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1605943
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares